PE20220943A1 - Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad - Google Patents

Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad

Info

Publication number
PE20220943A1
PE20220943A1 PE2022000057A PE2022000057A PE20220943A1 PE 20220943 A1 PE20220943 A1 PE 20220943A1 PE 2022000057 A PE2022000057 A PE 2022000057A PE 2022000057 A PE2022000057 A PE 2022000057A PE 20220943 A1 PE20220943 A1 PE 20220943A1
Authority
PE
Peru
Prior art keywords
layer
present
discharge
composition
venirunad
Prior art date
Application number
PE2022000057A
Other languages
English (en)
Inventor
Corswant Christian Von
Laleh Maleki
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20220943A1 publication Critical patent/PE20220943A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica de multiples particulas que comprende una pluralidad de granulos, donde cada granulo comprende: un nucleo; una capa de IFA sobre el nucleo, donde dicha capa comprende verinurad o una sal farmaceuticamente aceptable del mismo; una capa de polimero que controla la velocidad sobre la capa de IFA, tal como etilcelulosa, polivinilpirrolidona, hidroxipropilcelulosa, celulosa microcristalina; y una capa de alginato de sodio sobre la capa de polimero que controla la velocidad de liberacion presente en una cantidad entre 15% en peso y 25% en peso. Adicionalmente, la composicion de la presente invencion comprende un inhibidor de la xantina oxidasa tal como el alopurinol, presente en la capa de IFA. Dicha composicion es resistente a la descarga de dosis inducida por alcohol (ADD), siendo util en el tratamiento de hiperuricemia, gota, artritis, entre otros.
PE2022000057A 2019-07-16 2020-07-15 Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad PE20220943A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962874691P 2019-07-16 2019-07-16
PCT/EP2020/069941 WO2021009197A1 (en) 2019-07-16 2020-07-15 Dose dumping resistant pharmaceutical compositions comrising verinurad

Publications (1)

Publication Number Publication Date
PE20220943A1 true PE20220943A1 (es) 2022-05-31

Family

ID=71670235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000057A PE20220943A1 (es) 2019-07-16 2020-07-15 Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad

Country Status (18)

Country Link
US (1) US20230037277A9 (es)
EP (1) EP3999041A1 (es)
JP (1) JP2022541482A (es)
KR (1) KR20220035156A (es)
CN (1) CN114126610A (es)
AR (1) AR119421A1 (es)
AU (1) AU2020313310A1 (es)
BR (1) BR112022000349A2 (es)
CA (1) CA3145997A1 (es)
CL (1) CL2022000095A1 (es)
CO (1) CO2022000211A2 (es)
CR (1) CR20220069A (es)
DO (1) DOP2022000004A (es)
IL (1) IL289533A (es)
MX (1) MX2022000619A (es)
PE (1) PE20220943A1 (es)
TW (1) TW202122083A (es)
WO (1) WO2021009197A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112013003581B8 (pt) * 2010-08-18 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica gastro resistente, que compreende um ou mais sais do ácido algínico, e seu processo de produção
US20170065528A1 (en) * 2014-03-03 2017-03-09 Sensient Colors Llc Alcohol-Resistant, Dose Dumping Protective Enteric Drug Film Coating
US20180360761A1 (en) * 2015-12-08 2018-12-20 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of urat1

Also Published As

Publication number Publication date
AR119421A1 (es) 2021-12-15
JP2022541482A (ja) 2022-09-26
CR20220069A (es) 2022-03-24
US20220257522A1 (en) 2022-08-18
CL2022000095A1 (es) 2022-11-11
CA3145997A1 (en) 2021-01-21
US20230037277A9 (en) 2023-02-02
WO2021009197A1 (en) 2021-01-21
AU2020313310A1 (en) 2022-02-24
EP3999041A1 (en) 2022-05-25
BR112022000349A2 (pt) 2022-05-10
CN114126610A (zh) 2022-03-01
MX2022000619A (es) 2022-03-11
DOP2022000004A (es) 2022-03-15
TW202122083A (zh) 2021-06-16
IL289533A (en) 2022-03-01
KR20220035156A (ko) 2022-03-21
CO2022000211A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
Shiraki et al. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
BR112013002182B8 (pt) Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
PE20190390A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
US10526338B2 (en) Functionalized pentanoic acids for use influenza viral infections
US20200231577A1 (en) Aryl substituted pyrimidines for use influenza virus infection
BR112018011777A2 (pt) composições de fenfluramina e métodos para o preparo das mesmas
PE20061345A1 (es) Composicion farmaceutica que comprende sorafenib
NO20062082L (no) Pellets inneholdende venlafaksinhydroklorid
PE20070698A1 (es) Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
AR081539A1 (es) Composicion a base de fexofenadina y procedimiento de preparacion, sobre o comprimido, uso de la composicion
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
PE20220943A1 (es) Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad
CO6220902A2 (es) Formulacion en polvo del valganciclovir
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
CR20120061A (es) Tableta
Jiménez-Meléndez et al. In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites
Abdelnabi et al. Antiviral strategies against Chikungunya virus
Gaisina et al. Optimization of 4-aminopiperidines as inhibitors of influenza A viral entry that are synergistic with oseltamivir
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CN111479566B (zh) 用于治疗病毒和细菌感染的新mek抑制剂
Vanderlinden et al. A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin